2021 American Transplant Congress
Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients
Massachusetts General Hospital, Boston, MA
*Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…2021 American Transplant Congress
Clinical Outcomes and Management of Covid-19 Patients Among Kidney Transplant Recipients: A Systematic Review
*Purpose: We aim to systematically review published literature and synthesize the evidence available on therapeutic interventions and clinical outcomes used in the management of COVID-19…2021 American Transplant Congress
Real-world Treatment Patterns of Antiviral Agents for Cytomegalovirus Among Adult Kidney Transplant Recipients: A USRDS-Medicare Linked Database Study
*Purpose: Cytomegalovirus (CMV) is a common viral pathogen among kidney transplant recipients (KTRs). Although guidelines recommend the use of prophylaxis or pre-emptive antiviral (AV) therapy…2021 American Transplant Congress
Impact of Cytomegalovirus Prophylaxis on Herpes Simplex and Varicella Zoster Virus Infections in Kidney Transplant Recipients
*Purpose: To assess the impact of cytomegalovirus (CMV) targeted antiviral prophylaxis on the development of herpes simplex (HSV) and varicella zoster (VZV) infections after kidney…2021 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant Recipients Treated with Remdesivir and Convalescent Plasma for Covid-19 at the Largest Transplant Center in the United States
Miami Transplant Institute, Jackson Health System, Miami, FL
*Purpose: Solid organ transplant recipients (SOTr) are at high risk for severe disease with SARS-CoV-2. Data on efficacy of potential treatment options and long-term outcomes…2021 American Transplant Congress
Longitudinal Antibody Response and Viral Loads in Covid-infected Organ Transplant Recipients
*Purpose: The full spectrum of COVID-19 disease and the impact of disease severity on antibody response and viral shedding dynamics in transplant patients is unclear.…2021 American Transplant Congress
Leflunomide Therapy for Treatment of Bk Viremia in Pediatric Kidney Transplant Recipients
*Purpose: BK viremia (BKV) after kidney transplantation (KT) poses significant risk for BK virus-associated nephropathy (BKVN) and impacts graft survival. Conventional treatment involves reduction of…2021 American Transplant Congress
Influence of Induction Therapy and Antiretroviral Regimen on Outcomes in HIV Positive Renal Transplant Recipients
*Purpose: Transplantation of HIV+ individuals has become more common over the past decade with increasing data supporting good outcomes. Questions remain regarding the impact of…2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 14
- Next Page »